UPDATE | October 2, 2025

What are the keys to making rare disease drug development sustainable?

  • MAIL

What are the keys to making rare disease drug development sustainable


Just as complex molecules and large‑scale commercial projects demand the highest standards, niche rare‑disease drugs do too.  Taehyeong Kim, our associate director of project management, says an end‑to‑end CDMO delivers speed, quality, and sustainability—turning innovation into viable business. 


Read more in the Pharma’s Almanac commentary.

What are the keys to making rare disease drug development sustainable


Just as complex molecules and large‑scale commercial projects demand the highest standards, niche rare‑disease drugs do too.  Taehyeong Kim, our associate director of project management, says an end‑to‑end CDMO delivers speed, quality, and sustainability—turning innovation into viable business. 


Read more in the Pharma’s Almanac commentary.

Share article

  • MAIL

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required